Intercept Pharmaceuticals, Inc. (ICPT)
Nov 8, 2023 - ICPT was delisted (reason: acquired by Alfasigma)
19.00
0.00 (0.00%)
Inactive · Last trade price
on Nov 7, 2023
Intercept Pharmaceuticals Revenue
Intercept Pharmaceuticals had revenue of $88.79M in the quarter ending September 30, 2023, with 14.44% growth. This brings the company's revenue in the last twelve months to $317.68M, up 14.64% year-over-year. In the year 2022, Intercept Pharmaceuticals had annual revenue of $285.71M with 9.57% growth.
Revenue (ttm)
$317.68M
Revenue Growth
+14.64%
P/S Ratio
2.50
Revenue / Employee
$931,625
Employees
341
Market Cap
794.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 285.71M | 24.96M | 9.57% |
Dec 31, 2021 | 260.75M | 26.78M | 11.45% |
Dec 31, 2020 | 233.97M | -18.03M | -7.16% |
Dec 31, 2019 | 252.00M | 72.20M | 40.15% |
Dec 31, 2018 | 179.80M | 48.85M | 37.30% |
Dec 31, 2017 | 130.96M | 106.01M | 424.85% |
Dec 31, 2016 | 24.95M | 22.17M | 796.87% |
Dec 31, 2015 | 2.78M | 1.04M | 59.70% |
Dec 31, 2014 | 1.74M | 120.00K | 7.40% |
Dec 31, 2013 | 1.62M | -824.11K | -33.69% |
Dec 31, 2012 | 2.45M | 640.98K | 35.51% |
Dec 31, 2011 | 1.81M | - | - |
Dec 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionICPT News
- 11 days ago - US FDA declines full approval for Intercept's liver disease drug - Reuters
- 11 days ago - Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA) - GlobeNewsWire
- 2 months ago - FDA advisers vote against confirmatory data for Intercept's liver disease drug - Reuters
- 2 months ago - FDA staff raises efficacy concerns over Intercept's liver disease drug - Reuters
- 9 months ago - Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC - GlobeNewsWire
- 1 year ago - Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. - GlobeNewsWire
- 1 year ago - Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. - Business Wire
- 1 year ago - Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc. - Business Wire